Why did it happened? These were large double blind trials with low p values. Why is that (and that is not only Alexion) that you frequently have great double blind phase II and phase II results followed by a bomb in the pivotal trial? Anybody has any good explanation?
Everyone says how wonderful alexion trial was. They had an 18 percent reduction of events with a p value of .08 in a 3 or 4 thousand patient trial
mcu had a 37 percent reduction with a p value of .028 in a 300 patient arm
Market Data 
Markets 
AI
